The estimated Net Worth of Dennis M Lanfear is at least 22.9 百万$ dollars as of 22 November 2023. Mr. Lanfear owns over 299,940 units of Coherus Biosciences Inc stock worth over 1,269,875$ and over the last 16 years he sold CHRS stock worth over 16,288,433$. In addition, he makes 5,361,710$ as Chairman of the Board、 President、 Chief Executive Officer at Coherus Biosciences Inc.
Sign up
Mr. Lanfear CHRS stock SEC Form 4 insiders trading
Dennis has made over 10 trades of the Coherus Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 299,940 units of CHRS stock worth 425,915$ on 22 November 2023.
The largest trade he's ever made was selling 825,000 units of Coherus Biosciences Inc stock on 20 November 2019 worth over 14,850,000$. On average, Dennis trades about 39,980 units every 75 days since 2008. As of 22 November 2023 he still owns at least 954,793 units of Coherus Biosciences Inc stock.
You can see the complete history of Mr. Lanfear stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dennis Lanfear biography
Dennis M. Lanfear serves as Chairman of the Board, President, Chief Executive Officer of the Company. He is our co-founder and has served as our President and Chief Executive Officer and as a member of our Board of Directors since our inception in September 2010. Mr. Lanfear previously was President of InteKrin Therapeutics Inc., a biopharmaceutical company, from 2005 to May 2010. Prior to that, Mr. Lanfear served in various senior leadership roles at Amgen Inc., a biopharmaceutical company from 1986 to 1999. While at Amgen, Mr. Lanfear had key leadership positions in the Process Development department, which under his management became an area of key strategic advantage for Amgen. Mr. Lanfear has also held senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins and directed efforts from preclinical studies to Phase 3 clinical trials at Amgen. Mr. Lanfear holds B.S. degrees in Chemical Engineering and Biochemistry from Michigan State University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.
What is the salary of Dennis Lanfear?
As the Chairman of the Board、 President、 Chief Executive Officer of Coherus Biosciences Inc, the total compensation of Dennis Lanfear at Coherus Biosciences Inc is 5,361,710$. There are no executives at Coherus Biosciences Inc getting paid more.
How old is Dennis Lanfear?
Dennis Lanfear is 64, he's been the Chairman of the Board、 President、 Chief Executive Officer of Coherus Biosciences Inc since 2016. There are 6 older and 9 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.
What's Dennis Lanfear's mailing address?
Dennis's mailing address filed with the SEC is C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.
Insiders trading at Coherus Biosciences Inc
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over 94,360,509$ worth of Coherus Biosciences Inc stock and bought 594,589 units worth 8,026,656$ . The most active insiders traders include Llc Fmr、August J. Troendle、James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of 64,928$. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth 100,180$.
What does Coherus Biosciences Inc do?
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
What does Coherus Biosciences Inc's logo look like?
Complete history of Mr. Lanfear stock trades at Coherus Biosciences Inc、Insmed Inc
Coherus Biosciences Inc executives and stock owners
Coherus Biosciences Inc executives and other stock owners filed with the SEC include:
-
Dennis Lanfear,
Chairman of the Board, President, Chief Executive Officer -
Jean-Frederic Viret,
Chief Financial Officer -
Dennis M. Lanfear,
Chairman, Pres & CEO -
Vincent Anicetti,
Chief Operating Officer -
Vladimir Vexler,
Chief Scientific Officer -
Vladimir Vexler,
Chief Scientific Officer -
Mats Wahlstrom,
Lead Independent Director -
V. Bryan Lawlis,
Independent Director -
Mary Szela,
Independent Director -
Ali Satvat,
Independent Director -
James Healy,
Independent Director -
Samuel Nussbaum,
Independent Director -
Kimberly Tzoumakas,
Director -
Thomas Fitzpatrick,
Chief Legal Officer -
Dr. Barbara K. Finck M.D.,
Acting Chief Medical Officer -
Richard L. Hameister,
Chief Quality Officer -
Michael Chen,
Sr. VP of Commercial Analytics & Trade -
Michael A. Fleming,
Chief Strategy Officer -
Rebecca Sunshine,
Exec. VP of HR -
Chris Thompson,
Exec. VP of Sales -
McDavid Stilwell,
Chief Financial Officer -
Alan C. Herman,
Chief Scientific Officer -
August J. Troendle,
Director -
Christos Richards,
Director -
Peter K. Watler,
Chief Technical Officer -
Barbara K Finck,
Chief Medical Officer -
Rita A Karachun,
-
Llc Fmr,
10% owner -
Biosimilar L.P.Kkr Biosimil...,
-
Eli & Co Lilly Ventures Fun...,
-
Sankyo Company, Ltd Daiichi,
-
Georgia Erbez,
-
Alan C Mendelson,
Director -
Lee Nisley Newcomer,
-
Mark Stolper,
-
Charles W. Newton,
-
Jill O'donnell Tormey,
-
Michael Lee Ryan,
-
Paul Reider,
Chief Commercial Officer -
Mc David Stilwell,
Chief Financial Officer -
Bryan J Mc Michael,
Chief Financial Officer